WAVE Life Sciences, a preclinical biotech developing optimized RNA therapies for rare diseases, raised $102 million by offering 6.4 million shares at $16, the midpoint of the range of $15 to $17. The company originally planned to offer 5.0 million shares. Existing investors and Teva plan to buy $62 million on the IPO (61% of the deal). WAVE Life Sciences plans to list on the Nasdaq under the symbol WVE. Jefferies and Leerink Partners acted as lead managers on the deal.
